Glaxosmithkline Total Debt

GSK -  USA Stock  

USD 40.10  0.60  1.52%

Glaxosmithkline Plc ADR fundamentals help investors to digest information that contributes to Glaxosmithkline Plc's financial success or failures. It also enables traders to predict the movement of Glaxosmithkline Stock. This fundamental analysis module provides a way for investors to measures Glaxosmithkline Plc's intrinsic value by examining all of its available economic and financial indicators and drivers, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Glaxosmithkline Plc stock. Please note, this module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Search Total Debt 

The current Total Debt is estimated to decrease to about 26 B.

Glaxosmithkline Total Debt Analysis

Glaxosmithkline Plc's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Glaxosmithkline Plc Total Debt

25.95 BillionShare
Total Debt 
More About Total Debt | All Equity Analysis

Current Glaxosmithkline Plc Total Debt

  26.22 B  
Most of Glaxosmithkline Plc's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Glaxosmithkline Plc ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Glaxosmithkline Total Debt Driver Correlations

Understanding the fundamental principles of building solid financial models for Glaxosmithkline Plc is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Total Debt. Since Glaxosmithkline Plc's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Glaxosmithkline Plc's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Glaxosmithkline Plc's interrelated accounts and indicators.

Glaxosmithkline Total Debt Historical Pattern

Today, most investors in Glaxosmithkline Plc Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Glaxosmithkline Plc's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Glaxosmithkline Plc total debt as a starting point in their analysis.
 Glaxosmithkline Plc Total Debt 
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Compare to competition

Based on the latest financial disclosure, Glaxosmithkline Plc ADR has a Total Debt of 26.22 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The total debt for all United States stocks is significantly lower than that of the firm.
Glaxosmithkline Plc ADR is rated as one of the top companies in total debt category among related companies. Total debt of Drug Manufacturers—General industry is currently estimated at about 28.85 Billion. Glaxosmithkline Plc totals roughly 26.22 Billion in total debt claiming about 91% of equities under Drug Manufacturers—General industry.
Total debt  Revenue  Workforce  Capitalization  Valuation

Glaxosmithkline Plc Current Valuation Drivers

We derive many important indicators used in calculating different scores of Glaxosmithkline Plc from analyzing Glaxosmithkline Plc's financial statements. These drivers represent accounts that assess Glaxosmithkline Plc's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Glaxosmithkline Plc's important valuation drivers and their relationship over time.
201620172018201920202021 (projected)
Net Income Per Employee9.16 K15.56 K37.94 K46.71 K60.95 K49.41 K
Revenue Per Employee280.09 K306.57 K322.77 K339.45 K361.51 K312.13 K
Average Assets57.49 B58.16 B57.62 B72.23 B82.59 B74.56 B
Earnings Before Interest Taxes and Depreciation Amortization EBITDA4.5 B6.56 B7.37 B9.64 B10.29 B10.01 B
Earnings Before Interest Taxes and Depreciation Amortization USD5.56 B8.86 B9.35 B12.69 B14.1 B14.1 B
Earnings before Tax1.79 B2.89 B4.38 B5.6 B6.33 B5.54 B
Average Equity1.16 B937.75 M2.97 B7.7 B13.89 B14.99 B
Enterprise Value121.67 B114.19 B133.7 B163.23 B130.58 B146.44 B
Free Cash Flow6.66 B6.99 B8.57 B8.36 B8.94 B8.65 B
Invested Capital29.23 B19.77 B34.77 B39.93 B38.72 B37.54 B
Invested Capital Average30.21 B22.83 B33.99 B40.41 B41.44 B39.44 B
Market Capitalization103.23 B95.21 B102.64 B126.38 B99.05 B98.94 B
Tangible Asset Value34.34 B33.09 B35.08 B38.17 B40.01 B39.8 B
Working Capital(2.29 B)(10.66 B)(5.56 B)(4.56 B)(1.9 B)(2.05 B)

Glaxosmithkline Fundamentals

About Glaxosmithkline Plc Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Glaxosmithkline Plc ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Glaxosmithkline Plc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Glaxosmithkline Plc ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2021
Total Debt27.1 B26 B
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Glaxosmithkline Plc operates under Drug Manufacturers - General classification in the United States and is traded on New York Stock Exchange. It employs 94066 people.

Glaxosmithkline Plc Investors Sentiment

The influence of Glaxosmithkline Plc's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Glaxosmithkline. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - GSK

Glaxosmithkline Plc ADR Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Glaxosmithkline Plc ADR. What is your judgment towards investing in Glaxosmithkline Plc ADR? Are you bullish or bearish?
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Glaxosmithkline Plc ADR using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Glaxosmithkline Plc Piotroski F Score and Glaxosmithkline Plc Altman Z Score analysis. Note that the Glaxosmithkline Plc ADR information on this page should be used as a complementary analysis to other Glaxosmithkline Plc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Glaxosmithkline Stock analysis

When running Glaxosmithkline Plc ADR price analysis, check to measure Glaxosmithkline Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaxosmithkline Plc is operating at the current time. Most of Glaxosmithkline Plc's value examination focuses on studying past and present price action to predict the probability of Glaxosmithkline Plc's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Glaxosmithkline Plc's price. Additionally, you may evaluate how the addition of Glaxosmithkline Plc to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Transaction History
View history of all your transactions and understand their impact on performance
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Equity Valuation
Check real value of public entities based on technical and fundamental data
The market value of Glaxosmithkline Plc ADR is measured differently than its book value, which is the value of Glaxosmithkline that is recorded on the company's balance sheet. Investors also form their own opinion of Glaxosmithkline Plc's value that differs from its market value or its book value, called intrinsic value, which is Glaxosmithkline Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Glaxosmithkline Plc's market value can be influenced by many factors that don't directly affect Glaxosmithkline Plc ADR underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Glaxosmithkline Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine Glaxosmithkline Plc value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Glaxosmithkline Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.